The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease
Open Access
- 13 June 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5680
Abstract
Stroke, the third leading cause of death worldwide, is a major cause of functional disability. Cerebral ischemia causes a rapid elevation of adenosine, the main neuromodulator in the brain. The inhibition of adenosine A2A receptors (A2ARs) has been introduced as a potential target in neurodegenerative disorders involving extracellular adenosine elevation. Istradefylline, a selective A2AR antagonist, has been approved for Parkinson’s disease (PD) adjunctive therapy and showed neuroprotective effects in PD and Alzheimer’s disease. However, the role of A2ARs in post-stroke neuronal damage and behavioral deficits remains unclear. We recently showed that A2AR antagonism prevented the adenosine-induced post-hypoxia synaptic potentiation of glutamatergic neurotransmission following the hypoxia/reperfusion of hippocampal slices. Here, we investigated the potential neuroprotective effects of istradefylline in male Sprague-Dawley rats subjected to pial vessel disruption (PVD) used to model a small-vessel stroke. Rats were treated with either a vehicle control or istradefylline (3 mg/kg i.p.) following PVD surgery for three days. Istradefylline administration prevented anxiety and depressive-like behaviors caused by PVD stroke. In addition, istradefylline significantly attenuated ischemia-induced cognitive impairment and motor deficits. Moreover, istradefylline markedly reduced hippocampal neurodegeneration, as well as GFAP/Iba-1, TNF-α, nNOS, and iNOS levels after PVD, but prevented the downregulation of anti-inflammatory markers TGF-β1 and IL-4. Together, these results suggest a molecular link between stroke and PD and that the anti-PD drug istradefylline displays translational potential for drug repurposing as a neuroprotective agent for cerebral ischemic damage.Keywords
All Related Versions
Funding Information
- Heart and Stroke Foundation of Canada (G-16-00014633, SHRF CID #5146, RGPIN-2015-03850)
- Saskatchewan Health Research Foundation Collaborative Innovation and Development Grant (G-16-00014633, SHRF CID #5146, RGPIN-2015-03850)
- Natural Sciences and Engineering Research Council of Canada (G-16-00014633, SHRF CID #5146, RGPIN-2015-03850)
- University of Saskatchewan (G-16-00014633, SHRF CID #5146, RGPIN-2015-03850)
This publication has 100 references indexed in Scilit:
- Associations between cerebrovascular risk factors and parkinson diseaseAnnals of Neurology, 2019
- Involvement of matrix metalloproteinases‐2 and ‐9 in the formation of a lacuna‐like cerebral cavityJournal of Neuroscience Research, 2013
- Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's diseaseMovement Disorders, 2013
- Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)Annals of Neurology, 2008
- Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanismsAnnals of Neurology, 2008
- Stroke and the Risk of Alzheimer DiseaseArchives of Neurology, 2003
- Unusual topographical pattern of proximal astrogliosis around a cortical devascularizing lesionJournal of Neuroscience Research, 2003
- Prospective study of caffeine consumption and risk of Parkinson's disease in men and womenAnnals of Neurology, 2001
- Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated MonkeysExperimental Neurology, 2000
- Involvement of adenosine in ischemic and postischemic calcium regulationMolecular and Chemical Neuropathology, 1993